THERAPY DOSSIER · th-95c23ca13fac

Human umbilical cord-derived mesenchymal stem cells pretreated with angiotensin II

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31176170 ↗2019Reported benefit

Human umbilical cord mesenchymal stem cells pretreated with Angiotensin-II attenuate pancreas injury of rats with severe acute pancreatitis.

RatOtherIntravenous injection via the tail vein12 hours after induction of severe acute pancreatitis

Model: Severe acute pancreatitis in rats; induction method not stated in the abstract

Angiotensin II-pretreated human umbilical cord mesenchymal stem cells significantly inhibited pancreatic injury, reducing pancreatitis severity scores and serum amylase and lipase compared with untreated cells. Conditioned medium from the pretreated cells reduced HUVEC apoptosis and increased tube…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…